Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER THERAPY

Combining checkpoint inhibition and targeted therapy in melanoma

The combination of BRAF and MEK inhibition and anti-PD-1 is tolerable and has promising efficacy, which warrants further investigation into its use as melanoma therapy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Combined checkpoint inhibition and targeted therapy for melanoma.

References

  1. 1.

    Long, G. V. et al. J. Clin. Oncol. 36, 667–673 (2018).

    CAS  Article  Google Scholar 

  2. 2.

    Larkin, J. et al. N. Engl. J. Med. 371, 1867–1876 (2014).

    Article  Google Scholar 

  3. 3.

    Long, G. V. et al. Am. J. Clin. Oncol. 36, 9503–9503 (2018).

    Article  Google Scholar 

  4. 4.

    Hodi, F. S. et al. Lancet Oncol. 19, 1480–1492 (2018).

    CAS  Article  Google Scholar 

  5. 5.

    Ribas, A. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0476-5 (2019).

    CAS  Article  Google Scholar 

  6. 6.

    Sullivan, R. J. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0474-7 (2019).

    CAS  Article  Google Scholar 

  7. 7.

    Ascierto, P. A. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0448-9 (2019).

    CAS  Article  Google Scholar 

  8. 8.

    Robert, L., Ribas, A. & Hu-Lieskovan, S. Semin. Immunol. 28, 73–80 (2016).

    CAS  Article  Google Scholar 

  9. 9.

    Wilmott, J. S. et al. Clin. Cancer Res. 18, 1386–1394 (2012).

    CAS  Article  Google Scholar 

  10. 10.

    Frederick, D. T. et al. Clin. Cancer Res. 19, 1225–1231 (2013).

    CAS  Article  Google Scholar 

  11. 11.

    Hu-Lieskovan, S. et al. Sci. Transl. Med. 7, 279ra241 (2015).

    Article  Google Scholar 

  12. 12.

    Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. N. Engl. J. Med. 368, 1365–1366 (2013).

    CAS  Article  Google Scholar 

  13. 13.

    Minor, D. R., Puzanov, I., Callahan, M. K., Hug, B. A. & Hoos, A. Pigment Cell Melanoma Res. 28, 611–612 (2015).

    Article  Google Scholar 

  14. 14.

    Deken, M. A. et al. OncoImmunology 5, e1238557 (2016).

    Article  Google Scholar 

  15. 15.

    Rozeman, E. A. et al. Ann. Oncol. 29, mdy424-056 (2018).

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Christian U. Blank.

Ethics declarations

Competing interests

E.A.R. received travel support from MSD and NanoString. C.U.B. reports personal fees as a consultant advisor for Bristol-Myers Squibb, Merck Sharpe Dohme, Roche, Novartis, Lilly, Pfizer, GlaxoSmithKline, GenMab and Pierre Fabre and has received research grants from Bristol-Myers Squibb, Novartis, and NanoString, all paid to the institution (Netherlands Cancer Institute).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rozeman, E.A., Blank, C.U. Combining checkpoint inhibition and targeted therapy in melanoma. Nat Med 25, 879–882 (2019). https://doi.org/10.1038/s41591-019-0482-7

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing